Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.75 |
| ▸ | P2RY6 | Q15077 | 13/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686755 | 1.00 | P2RY2 (0.75) | P2RY2P2RY6P2RY4 | |
| SCHEMBL18785151 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL12595472 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL18785150 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL39904 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL29360821 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL154172 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL532547 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL18785149 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL308618 | 0.99 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | FERRER INTERNACIONAL, S.A. (ES) | 2026-01-27 | — | — | US | disclosed |
| CN-113784706-B | Multi-layered pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and B vitamins, their preparation and use | 菲尔若国际公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-115666587-A | N4-hydroxycytidine and derivatives and related antiviral uses thereof | 埃默里大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20220160744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2022-05-26 | — | — | US | disclosed |
| EP-3965744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | Ferrer Internacional, S.A. (ES) | 2022-03-16 | — | — | EP | disclosed |
| CN-113784706-A | Multi-layered pharmaceutical or nutraceutical solid dosage form comprising pyrimidine and/or purine derivatives and B vitamins, preparation and use thereof | 菲尔若国际公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020224795-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | P2RY10, TYMP, P2RY12 | P2RY2 42/4885P2RY6 17/4885P2RY4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.